Skip to main content

Cancer 62 Day Patient Tracking List (CANPTL) data collection

Cancer 62 Day Patient Tracking List (CANPTL) data collection.

Background to the collection

Frequency: Weekly


The 'Cancer 62 Day Patient Tracking List' (CANPTL) collection is a weekly snapshot which shows the number of patients on the cancer 62-day pathway, who are at risk of breaching the 62-day standards.

From the 23 November 2020, this collection has been remodelled to also include waiting list breakdown by suspected tumour groups 62-day screening, consultant upgrades and further granularity about the start of treatment.


Launch and submission dates

The remodelled PTL Dataset Collection will be launched the week commencing 23 November 2020, for data collections of the week prior (week end the 22 November 2020).

The data collection will open each Monday and the submission deadline will be at the end of the day on Wednesday for submission of the previous week’s data. By exception this timetable may change - for example, to accommodate bank holidays.


SDCS guidance

For guidance using the Strategic Data Collection Service (SDCS), refer to the SDCS guidance page.


National Cancer 62 Day Patient Tracking List Dataset recording guidance

The dataset

The Cancer 62 Day PTL (Patient Tracking List) data collection is a weekly snapshot that captures the number of patients on a cancer 62-day pathway. This includes patients on a 62-day pathway who have had a decision made to treat their cancer, and patients who have not had a decision made to treat their cancer waiting until 23:59 Sunday of the reporting week. This also includes the number of first definitive treatments on a 62-day pathway following an urgent suspected cancer referral in the reporting week up to 23:59 on Sunday.

The collection covers:

  • two months (62-day) wait from urgent referral to first definitive treatment
  • two months (62-day) wait from urgent referral from screening service
  • two months (62-day) wait from consultant upgrade
  • patients referred on the breast symptomatic standard

Scope

The collection is submitted by NHS trusts that provide cancer services.
This includes:

  • patients on a 62-day pathway who are referred for urgent suspected cancer referral
  • patients on a 62-day pathway following an urgent referral from an NHS Cancer Screening Programme (breast, cervical or bowel
  • patients referred following a breast symptomatic referral
  • patients on a 62-day pathway following a consultant upgrade

Removal from the PTL

A patient is removed from the 62-day pathway and PTL monitoring under the following circumstances:

  • When the organisation communicates to the patient that a cancer diagnosis has been excluded
  • when a first definitive treatment or permitted enabling treatment has been completed
  • Where a patient declines treatment
  • Where a patient chooses to receive treatment privately.
  • Death occurs before treatment

Inter-provider transfers

Where a trust refers a 62-day patient to another trust for treatment, the patient should be removed from the referring trust’s 62-day PTL and added to the receiving Trust’s PTL.
In such cases, the patients start date on the 62-day pathway remains the same (that is the patient must still be treated within 62 days of the clock start). 

Collection timeframe and deadline

Data should be provided for the collection covering the period of the previous Monday (from 00:00) to Sunday (to 23:59) prior to the collection submission window opening on the following Monday morning.

Returns should be submitted to the Strategic Data Collection Service by 17:00 on the Wednesday after the collection period ends. 

Sections 1 and 2 - pathway stage and tumour type

You should include patients waiting from referral/upgrade date by the number of days waited as at midnight Sunday of the reporting week.

Patients are recorded under time brackets for each individual tumour type according to how long they have been waiting on the pathway, the time brackets are as follows

  • day 0-28
  • day 29-62
  • day 63-104
  • day greater than 104 (that is, 105 days and more)

For each individual tumour type the number of patients passing 28 days,  62 days, and the number of patients passing 104 days in the last 7 days are recorded.

Urgent suspected cancer

Patients on a 62-day pathway who are referred for urgent suspected cancer.  

Patients are recorded according to the tumour type they are referred under.

If the patient has been transferred to another team within the trust on the suspicion of a different type of cancer, in this case the patient should be recorded under this tumour type and new team.

To ensure ease of collection and to make sure all metrics are feasible to be submitted accurately, we will not be asking to collect numbers of acute leukaemia waiters separately from haematological, nor testicular from urological.

Breast symptomatic

Patients referred on the breast symptomatic pathway (where cancer is not suspected).

Urgent screening

Patients referred urgently from one of the three national screening services (breast, bowel and cervical).

Patients who subsequently have their tumour type updated after investigations should continue to be recorded under the screening service they were referred from until they are removed from the PTL.

Consultant upgrade

Patients who have had their pathway upgraded from a referral to treatment (RTT) pathway to a 62-day pathway.

This covers patients with a first primary cancer only.

Section 1 - patients on 62-day target list without a decision to treat

You should include patients, as of 23:59 Sunday of the reporting week, patients that are waiting on the pathway to determine if they have cancer, or have had cancer diagnosed and have not yet had a decision to treat for their cancer.

Section 2 - patients on 62-day tracking list with a decision to treat

You should include patients, as of 23:59 Sunday are waiting on the pathway who have had a decision to treat their cancer but have not yet received their treatment for cancer.

Section 3 – patients on the 62-day urgent suspected cancer pathway who received their first definitive treatment

You should include those patients who received their first definitive treatment in the last 7 days on the 62-day urgent suspected cancer pathway. That is, those who were treated in the scope of sections 1.1 and 2.1 of the template in Annex A.

Patients are recorded under the time bracket that corresponds to when they received their first definitive treatment

  • by day 62 
  • between day 63-104
  • after day 104 (that is, 105 days and more)

The guidance relating to the Cancer Waiting Times should be referenced for definitions of what should be counted as a first definitive treatment.

For surgery, pathology may not be reported given the timescales, so for the purposes of this return patients should be included where the intention is to remove or debulk the tumour and the patient has confirmed or assumed cancer at the time of reporting.

Section 4 – Number of patients referred or upgraded in the last 7 days

You should include patients who, as of 23:59 Sunday, have been referred or upgraded in the last 7 days via either an urgent suspected cancer, breast symptomatic or urgent screening referral or upgraded onto the consultant upgrade pathway in the last 7 days.

Patients are recorded under the route and suspected cancer type for this part of the return.

For referrals this should include all referrals received by the trust either via E-RS or other routes, including where there are Appointment Slot Issues (ASI).

Section 5 – Number of patients first seen in last 7 days

You should include patients who, as of 23:59 Sunday, who have been first seen following an urgent suspected cancer referral (including non-site specific).

This is only collected for the urgent suspected cancer route and split by suspected cancer type.

The Cancer Waiting Times guidance version 11 alongside the clarification guidance should be reviewed for a definition of what counts as a first seen date.

Comments

To include details of any breaches in the last 7 days.


Data Provision Notice


Contact details

Any queries should be emailed to: england.cancerwaitsdata@nhs.net

Last edited: 25 May 2022 12:51 pm